What strategies can reduce development time and accelerate access to next-generation monoclonal antibodies (mAbs) in the evolving SARS-CoV-2 variant landscape?

Credit available for this activity expires: 1/26/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/999900?ecd=bdc_podcast_libsyn_mscpedu